久久亚洲国产成人影院-久久亚洲国产的中文-久久亚洲国产高清-久久亚洲国产精品-亚洲图片偷拍自拍-亚洲图色视频

Global EditionASIA 中文雙語(yǔ)Fran?ais
Business
Home / Business / Companies

Sanofi targets ground-breaking therapies with a new R&D strategy

chinadaily.com.cn | Updated: 2022-03-31 11:04
Share
Share - WeChat
John Reed, executive vice-president, global head of research and development at Sanofi. [Photo provided to chinadaily.com.cn]

"We are sharpening our R&D focus on first-in-class or best-in-class medicines and vaccines in order to address the world's most urgent healthcare needs", said John Reed, executive vice-president and head of Global R&D of Sanofi. He emphasized Sanofi's scientific mission when talking about the company's R&D strategy, "because patients are counting on us."

Reed, formerly the head of Roche Pharma Research and Early Development (pRED), joined Sanofi in 2018, where he participated in and witnessed a crucial strategic transformation of the company.

As an essential step in Sanofi's "Play to Win" strategy, announced in 2019, the company launched a new brand identity and purpose to highlight its corporate mission "Chase the miracles of science to improve people's lives" early this year.

Companies that implement rebranding will often make key strategic adjustments, and Sanofi is no exception. As an R&D-driven pharmaceutical company, Sanofi has made the transformation of its R&D strategy central to its rebranding initiatives.

"The pursuit of scientific miracles is a dynamic process, and the process of R&D is challenging, but we don't let the setbacks deter us from pushing forward and working to improve the lives of patients," Reed said.

A new transformation, a new ambition

Founded in 1973, Sanofi is a young global pharmaceutical company. In the past several decades, it has developed many breakthrough therapies, including Lantus (insulin glargine), Taxotere (anti-cancer drug), Lovenox (anti-coagulant), Aubagio (multiple sclerosis), and Cerezyme (Gaucher disease).

For almost half a century, Sanofi has been protecting lives with its vaccines, saving and transforming lives with its cutting-edge science, from primary care to the treatment of cancer and rare diseases. It took Sanofi only 32 years to go from being a small company to being one of the top pharmaceutical giants in the world, an astonishingly rapid ascent compared with century-old pharmaceutical companies.

Despite such extraordinary past achievements, Sanofi is reflecting on the most urgent healthcare needs which have yet to be resolved. Can innovation and R&D be refocused? Can products have greater clinical value? How to sustain long-term growth? According to Reed, Sanofi has strictly prioritized and reallocated resources for R&D.

Based on its expertise and experience with preventing and treating conditions from chronic diseases to rare diseases, Sanofi further optimizes resources to sharpen its R&D focus to first-in-class or best-in-class programs in vaccines and specialty care areas like immunology and oncology, where recent breakthroughs open up a world of new therapeutic opportunities.

A sign of Sanofi's progress is that in 2021 it added 36 phase I and phase II clinical development programs, a clear indication of its strong pipeline of early-stage projects. The company is also investing more in biologics – seen in the fact that they now represent over 70 percent of its pipeline.

According to Reed, Sanofi has prioritized multiple potentially transformative therapies in areas of high unmet patient need, including Dupixent, the world's first targeted biological agent that has been approved for treating moderate-to-severe atopic dermatitis, Fitusiran and Efanesoctocog alfa (BIVV001) for treatment of hemophilia, Amlitelimab for treatment of inflammatory disorders, Amcenestrant for treatment of breast cancer, RSV Vaccine Nirsevimab, and Tolebrutinib for treatment of multiple sclerosis.

Sanofi's changes are also evident in its financial performance. In the newly released 2021 annual financial report, specialty medicine has become Sanofi's most prominent business unit by sales for the first time, with R&D investment in specialty drug products accounting for 95 percent of the company's total R&D investment, up by about 50 percent from that of 2017.

1 2 3 Next   >>|
Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
CLOSE
 
主站蜘蛛池模板: 国产欧美在线观看 | 色一级片 | 在线观看精品视频一区二区三区 | 亚洲夜色 | 99九九精品国产高清自在线 | 日韩精品视频免费在线观看 | 亚洲 欧美 丝袜 | 亚洲乱人伦精品图片 | 久久精品国内一区二区三区 | 欧美日韩一级黄色片 | 国产极品精频在线观看 | 在线成人免费视频 | 成人做爰 | 拍拍拍又黄又爽无挡视频免费 | 国产美女91视频 | 男人使劲躁女人视频小v | 欧美兽皇video | 在线欧美精品二区三区 | 成人免费观看高清在线毛片 | 草草影院永久在线观看 | 亚洲日韩精品欧美一区二区一 | 亚洲国产精品a一区二区三区 | 国产欧美成人xxx视频 | 国产精品久久久久久久久久久久 | 国产高中生粉嫩无套第一次 | 六月丁香久久丫 | 黄a视频 | 欧美一级成人影院免费的 | 一本色道久久综合亚洲精品加 | 亚洲精品一区国产二区 | 最新毛片久热97免费精品视频 | 欧美一欧美一级毛片 | 97视频在线观看免费 | 亚洲激情 欧美 | 国产高清在线看免费视频观 | 国产v片在线播放免费观 | 免费观看欧美一级毛片 | 日韩亚洲成a人片在线观看 日韩亚洲精品不卡在线 | 不卡午夜视频 | 亚洲综合一区二区不卡 | 久9青青cao精品视频在线 |